Current Management Approaches for HAE-C1-INH
For many patients and their healthcare providers, treatment decisions still require balancing efficacy, convenience, speed, and tolerability.
Current HAE-C1-INH treatment guidelines emphasize achieving better disease control and sustained improvement in quality of life. Yet presently available medications don’t always make that goal easy to reach, leaving clinicians to navigate the inevitable trade-offs.1-4
Management strategies generally fall into three categories5:
Management strategies generally fall into three categories5:
On-demand treatment
to treat attacks as they occur
Short-term prophylaxis
before known triggers such as procedures or dental work
Long-term prophylaxis
to reduce attack frequency over time
Current therapies target different points in the bradykinin pathway, including C1-INH replacement, plasma kallikrein inhibition, and B2 receptor antagonism. Some of these therapies are effective, but burdensome to administer. Others are more convenient, but create uncertainty around speed or symptom control. Route of administration can influence whether patients treat early, a decision with real clinical consequences.
Delays matter
Inadequate initial treatment increases the risk of escalation, emergency care, and the anticipatory anxiety that compounds the burden of every future attack.4,6
Management Shouldn’t Mean Accepting Compromise1-3
Management Shouldn’t Mean Accepting Compromise1-3
Patients may learn to adapt to treatment burdens—but adaptation is not the ultimate goal.
For many patients with HAE-C1-INH, the burden extends beyond the attacks themselves. Managing treatment during unpredictable, time-sensitive events can carry significant practical and emotional strain.
The Wait-and-See Problem4,6
The Wait-and-See Problem4,6
One common pattern is the “wait-and-see” phenomenon—delaying treatment in hope that symptoms will not progress. Hesitation may be driven by treatment burden, including fear of injections, pain, inconvenience, or difficulty in quickly accessing therapy.
But delayed treatment can allow attacks to escalate, increasing pain, functional impairment, emergency care utilization, and anxiety around future attacks.
Stability Is Not Control1-3
Even patients considered “stable” may continue organizing daily life around medication access or fear of progression. The goal of HAE-C1-INH management is rapid, reliable attack resolution without compromising efficacy, tolerability, or convenience.
Acute oral treatment also challenges the assumption that on-demand care must involve injectable therapy.
Real person living with HAE.
C1-INH, C1-inhibitor; HAE, hereditary angioedema; HAE-C1-INH, hereditary angioedema due to C1-INH deficiency.
Uncover the trade-offs of HAE medications.
Join us in finding a path beyond the burdens of HAE.
REFERENCES
1. Zuraw BL, Bernstein JA, Lang DM, et al. A focused parameter update: hereditary angioedema, acquired C1 inhibitor deficiency, and angiotensin-converting enzyme inhibitor-associated angioedema. J Allergy Clin Immunol. 2013;131(6)1491-1493. doi:10.1016/j.jaci.2013.03.034
2. Radojicic C, Riedl MA, Craig TJ, et al. Patient perspectives on the treatment burden of injectable medication for hereditary angioedema. Allergy Asthma Proc. 2021;42(3):S4-S10. doi:10.2500/aap.2021.42.210025
3. Geba D, Sani JM, Gascon M, et al. Hereditary angioedema patients would prefer newer-generation oral prophylaxis. J Drug Assess. 2021;10(1):51-56. doi:10.1080/21556660.2020.1863699
4. Vázquez DO, Giavina-Bianchi P, Josviack D, et al. The 2025 WAO guidelines for the classification, diagnosis, and treatment of hereditary angioedema, with consideration of worldwide disparities. World Allergy Organ J. 2026;19(5):101335. doi:10.1016/j.waojou.2026.101335
5. Betschel SD, Banerji A, Busse PJ, et al. Hereditary angioedema: a review of the current and evolving treatment landscape. J Allergy Clin Immunol Pract. 2023;11(8):2315-2325. doi:10.1016/j.jaip.2023.04.017
6. Bork K, Anderson JT, Caballero T, et al. Assessment and management of disease burden and quality of life in patients with hereditary angioedema: a consensus report. Allergy Asthma Clin Immunol. 2021;17(1):40. doi:10.1186/s13223-021-00537-2